DARE — Daré Bioscience, Inc.

DARE Bioscience Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash Position: Ended 2025 with approximately $24.7 million in cash and cash equivalents.
• Working Capital: Approximately $3.4 million.
• Equity Financing: Raised about $20.8 million through common stock sales under an ATM facility.
• Non-Dilutive Funding: Received $13.6 million from the Gates Foundation, $4.5 million from ARPA-H, and $1.3 million from NIH grants, aiding in advancing multiple programs while managing shareholder dilution.
• Expenses: SG&A expenses decreased to $8.8 million from $9.2 million in 2024. R&D expenses significantly reduced to $5.5 million from $14.3 million in 2024, with contra R&D funding of $13.9 million noted as a key factor in total R&D investment.

2. Strategic Updates and Business Highlights:

• DARE to PLAY: The topical sildenafil cream for women launched pre-fulfillment prescribing in February 2026 across all 50 states. It is positioned as the first clinically studied topical product for female arousal, with a focus on rapid onset of action.
• DARE to RESTORE: A line of vaginal probiotics, with the first product, Flora Sync LF5, expected to launch in Q2 2026.
• DARE to RECLAIM: A monthly intravaginal ring for bioidentical hormone therapy targeting a $2.5 billion to $4.5 billion market, anticipated for 503B prescription fulfillment in 2027.
• Ovaprene: A non-hormonal contraceptive candidate in Phase III trials, with enrollment expected to complete in 2026.
• DARE-HPV: Aiming to advance into Phase II clinical studies with ARPA-H funding, targeting a significant unmet need in HPV treatment.

3. Forward Guidance and Outlook:

• Revenue from DARE to PLAY and Flora Sync LF5 expected to begin in Q2 2026.
• Continued focus on building a multi-product revenue profile across 2026 and 2027.
• Anticipated completion of Ovaprene enrollment in 2026, with data readout expected in 2027.
• Ongoing efforts to secure additional partnerships and expand market presence through telehealth and digital marketing strategies.

4. Bad News, Challenges, or Points of Concern:

• Regulatory Path: Ongoing discussions with the FDA regarding the 505(b)(2) regulatory pathway for sildenafil cream, with a need to align on clinical endpoints.
• Market Competition: The presence of compounded sildenafil products may pose challenges in differentiating DARE to PLAY, despite its clinical backing.
• Funding Dependence: While non-dilutive funding is beneficial, reliance on grants may pose risks if future funding opportunities are limited.

5. Notable Q&A Insights:

• Physician Engagement: There is a strong focus on educating healthcare providers about DARE to PLAY, with early prescription activity noted despite the product not yet being dispensed.
• Consumer Awareness: The company is leveraging both telehealth platforms and traditional provider education to drive awareness and adoption of its products.
• Market Positioning: The management emphasized the unique formulation of DARE to PLAY and the importance of clinical data in establishing credibility and trust among both providers and consumers.
• Strategic Partnerships: Future partnerships with telehealth platforms and clinical networks are anticipated to enhance market reach and patient acquisition strategies.

Overall, DARE Bioscience is positioned for growth with a robust pipeline and strategic focus on women's health, despite facing regulatory and competitive challenges.